Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and
exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System
to obtain repeated measurements of PAP and other hemodynamic parameters.
Elegible subjects will have a RHC to implant the CardioMEMS pulmonary artery (PA) Sensor
followed by a Baseline Period for the subject to become familiar with the system, its
measurements, how to send the data, and establish Baseline PA pressure. Alternately, the
subject may already have the CardioMEMS HF System and is willing to have the system
recalibrated in conjunction with RHC. Thereafter, the subject will be randomly assigned to 1
of 3 total daily doses of CS1 1:1:1; there will be 10 subjects assigned to each dose level.
Subjects will receive study drug treatment for 12 weeks. During the study, mPAP and other
hemodynamic parameters from CardioMEMS PA Sensor will be measured and data captured once
daily in the morning before the subject gets out of bed.
The data will be transferred electronically to a repository. The analysis will look at the
area under the curve (AUC) of mPAP and the doses will be compared to each other regarding
change from Baseline. In addition to the CardioMEMS HF System measurements, the subjects will
be followed for mortality and morbidity, important biomarkers as well as subjective,
functional, and structural parameters of importance for PAH, for the duration of the study.
Subjects will be enrolled for up to 22 weeks: a Screening Period of up to 2 weeks prior to
the start of the Baseline Period, a Baseline Period of up to 6 weeks prior to Randomization,
a Treatment Period of 12 weeks, and a Follow-up Period of 2 weeks.
The primary objective of the study is to obtain safety and tolerability data.